Cargando…
PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report
BACKGROUND: The optimal treatment and molecular landscape of recurrent clear cell carcinoma of the vulva (VCCC) are unknown. No reported data exist regarding the efficacy of anti-programmed death 1 (PD-1) immune checkpoint inhibition in VCCC. We report on a patient with chemotherapy-refractory recur...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254584/ https://www.ncbi.nlm.nih.gov/pubmed/34234460 http://dx.doi.org/10.2147/OTT.S309661 |
_version_ | 1783717758394957824 |
---|---|
author | Sachdeva, Manavi Ngoi, Natalie Y L Lim, Diana Poon, Michelle L M Thian, Yee Liang Lim, Yi Wan Lim, Siew Eng Tong, Pearl Lum, Jeffrey H Y Ng, Joseph Ilancheran, Arunachalam Domingo, Efren J Low, Jeffrey J H Tan, David S P |
author_facet | Sachdeva, Manavi Ngoi, Natalie Y L Lim, Diana Poon, Michelle L M Thian, Yee Liang Lim, Yi Wan Lim, Siew Eng Tong, Pearl Lum, Jeffrey H Y Ng, Joseph Ilancheran, Arunachalam Domingo, Efren J Low, Jeffrey J H Tan, David S P |
author_sort | Sachdeva, Manavi |
collection | PubMed |
description | BACKGROUND: The optimal treatment and molecular landscape of recurrent clear cell carcinoma of the vulva (VCCC) are unknown. No reported data exist regarding the efficacy of anti-programmed death 1 (PD-1) immune checkpoint inhibition in VCCC. We report on a patient with chemotherapy-refractory recurrent VCCC, who was found to have high tumor programmed death-ligand 1 (PD-L1) combined positive score (CPS), and subsequently experienced a durable partial response (PR), after treatment with off-label fifth-line pembrolizumab. CASE PRESENTATION: A forty-year-old Filipino woman presented to our center with recurrent VCCC that had progressed on multiple prior lines of cytotoxic chemotherapy. She had a large 25 cm fungating left groin tumor causing marked lower limb lymphedema, pain and limited mobility. PD-L1 CPS by immunohistochemistry was 45. She was treated with off-label pembrolizumab monotherapy and had a dramatic clinical, biochemical and radiological partial response. The progression-free survival of this patient’s VCCC after treatment with pembrolizumab, defined as the time from initiation of pembrolizumab until disease progression (by Response Evaluation Criteria in Solid Tumors (version 1.1)), was 8 months. While receiving pembrolizumab, she was diagnosed with concurrent secondary myelodysplastic syndrome with excess blasts (MDS-EB), thought to be related to her prior exposure to multiple lines of cytotoxic chemotherapy. This eventually progressed to acute myeloid leukemia (AML), leading to her demise. Overall survival from time of initiation of pembrolizumab till death was 16 months. CONCLUSION: Pembrolizumab was active in this patient with chemotherapy-refractory VCCC which harbored high PD-L1 CPS. Further studies to determine the role of immune check-point blockade in the treatment of VCCC are warranted. |
format | Online Article Text |
id | pubmed-8254584 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-82545842021-07-06 PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report Sachdeva, Manavi Ngoi, Natalie Y L Lim, Diana Poon, Michelle L M Thian, Yee Liang Lim, Yi Wan Lim, Siew Eng Tong, Pearl Lum, Jeffrey H Y Ng, Joseph Ilancheran, Arunachalam Domingo, Efren J Low, Jeffrey J H Tan, David S P Onco Targets Ther Case Report BACKGROUND: The optimal treatment and molecular landscape of recurrent clear cell carcinoma of the vulva (VCCC) are unknown. No reported data exist regarding the efficacy of anti-programmed death 1 (PD-1) immune checkpoint inhibition in VCCC. We report on a patient with chemotherapy-refractory recurrent VCCC, who was found to have high tumor programmed death-ligand 1 (PD-L1) combined positive score (CPS), and subsequently experienced a durable partial response (PR), after treatment with off-label fifth-line pembrolizumab. CASE PRESENTATION: A forty-year-old Filipino woman presented to our center with recurrent VCCC that had progressed on multiple prior lines of cytotoxic chemotherapy. She had a large 25 cm fungating left groin tumor causing marked lower limb lymphedema, pain and limited mobility. PD-L1 CPS by immunohistochemistry was 45. She was treated with off-label pembrolizumab monotherapy and had a dramatic clinical, biochemical and radiological partial response. The progression-free survival of this patient’s VCCC after treatment with pembrolizumab, defined as the time from initiation of pembrolizumab until disease progression (by Response Evaluation Criteria in Solid Tumors (version 1.1)), was 8 months. While receiving pembrolizumab, she was diagnosed with concurrent secondary myelodysplastic syndrome with excess blasts (MDS-EB), thought to be related to her prior exposure to multiple lines of cytotoxic chemotherapy. This eventually progressed to acute myeloid leukemia (AML), leading to her demise. Overall survival from time of initiation of pembrolizumab till death was 16 months. CONCLUSION: Pembrolizumab was active in this patient with chemotherapy-refractory VCCC which harbored high PD-L1 CPS. Further studies to determine the role of immune check-point blockade in the treatment of VCCC are warranted. Dove 2021-06-29 /pmc/articles/PMC8254584/ /pubmed/34234460 http://dx.doi.org/10.2147/OTT.S309661 Text en © 2021 Sachdeva et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Case Report Sachdeva, Manavi Ngoi, Natalie Y L Lim, Diana Poon, Michelle L M Thian, Yee Liang Lim, Yi Wan Lim, Siew Eng Tong, Pearl Lum, Jeffrey H Y Ng, Joseph Ilancheran, Arunachalam Domingo, Efren J Low, Jeffrey J H Tan, David S P PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report |
title | PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report |
title_full | PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report |
title_fullStr | PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report |
title_full_unstemmed | PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report |
title_short | PD-L1 Expressing Recurrent Clear Cell Carcinoma of the Vulva with Durable Partial Response to Pembrolizumab: A Case Report |
title_sort | pd-l1 expressing recurrent clear cell carcinoma of the vulva with durable partial response to pembrolizumab: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8254584/ https://www.ncbi.nlm.nih.gov/pubmed/34234460 http://dx.doi.org/10.2147/OTT.S309661 |
work_keys_str_mv | AT sachdevamanavi pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT ngoinatalieyl pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT limdiana pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT poonmichellelm pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT thianyeeliang pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT limyiwan pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT limsieweng pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT tongpearl pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT lumjeffreyhy pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT ngjoseph pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT ilancheranarunachalam pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT domingoefrenj pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT lowjeffreyjh pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport AT tandavidsp pdl1expressingrecurrentclearcellcarcinomaofthevulvawithdurablepartialresponsetopembrolizumabacasereport |